The Lancet Infectious Diseases
Издатель: Elsevier · ISSN 1473-3099 · 79 статей
- Merck's alimatravir licensing deal receives mixed response
- WHO updates guidelines for visceral leishmaniasis
- The Global Fund supports malaria response in DR Congo
- Infection prevention and control gaps in Pakistan
- Bruce Ribner
- Sneeze: The History and Science of the Common Cold, David Miles. August Books (2026), 352, £10·99, 13, ISBN: 978-1-804-36924-1
- The Silent Killer: The Untold Story of Humanity's Deadliest Infection and the Fight to Eradicate It, Liora Ashfield. independently published (2026), 104, £15·78, ISBN: 9798254726913
- Global burden of enteric infectious diseases, diarrhoeal diseases, and corresponding aetiologies, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
- Efficacy and safety of a 4-month quabodepistat, delamanid, and bedaquiline regimen for drug-susceptible pulmonary tuberculosis: a multicentre, open-label, randomised, proof-of-concept, non-inferiority, phase 2b/c trial
- Effectiveness of oral care for the prevention of non-ventilator hospital-acquired pneumonia (HAPPEN): a multicentre, stepped-wedge, cluster-randomised trial in Australia
- Effect of a community-based behavioural intervention bundle to improve antibiotic use and patient management in Burkina Faso and DR Congo (CABU-EICO): a cluster-randomised controlled trial
- Safety and immunogenicity of mRNA-based mpox vaccine candidate BNT166a: an open-label, dose-escalation, first-in-human trial
- Improving the treatment of invasive fungal infections: novel antifungal and host-directed therapies
- Thelazia callipaeda: an emerging zoonotic eyeworm from Asia to Europe and North America
- Neutralising antibody responses to MPXV clades Ia, Ib, and IIb after infection or vaccination: a multicountry observational study
- Yellow fever vaccination in healthy Gambian children of different ages to establish safety and immunogenicity of a booster dose: a open-label, non-randomised, single-site, phase 3 vaccine trial
- Use of tocilizumab for severe hantavirus pulmonary syndrome: a MEURI case series with contextual comparisons
- Expert consensus on case definitions in human loiasis: a Delphi study
- Therapeutic plasma exchange and continuous renal replacement therapy for severe dengue with multiorgan failure: a case report and focused review
- A systematic review of Nipah virus disease epidemiological parameters, outbreaks, and mathematical models
- Understanding and exploiting superspreading to disrupt Mycobacterium tuberculosis transmission
- Calciphylaxis complicated by NDM-1-producing Pseudomonas aeruginosa: first experience with cefepime–zidebactam alongside phage therapy in the USA
- Lymphoma-like endoscopic appearance of lymphogranuloma venereum
- Evidence of artemisinin partial resistance in Zambia: a molecular epidemiology and clinical study
- When the fungus is susceptible, but the patient is not: reading antifungal susceptibility from bench to bedside
- Efficacy, safety, and immunogenicity of a nine-valent vaccine (ExPEC9V) for the prevention of invasive Escherichia coli disease in older adults: a phase 3, randomised, placebo-controlled trial (E.mbrace)
- Second-season observations after prophylaxis in the evaluation of the impact of nirsevimab in Galicia (NIRSE-GAL) study: mechanistic interpretation and implications for respiratory syncytial virus prevention strategy
- Cross-reactive T-cell responses against BDBV in humans after rVSVΔG-ZEBOV-GP vaccination
- Daptomycin for enterococcal bloodstream infections and endocarditis: reconciling clinical evidence, susceptibility testing, and regulatory frameworks
- Putting emotion back into pandemic numbers